contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-plc-financial-reporting-and-annual-general-meeting-in-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Partnerskabet Roche & Herantis Pharma kunne være en ”vinderkombination”…. https://x.com/ristopar/status/1998767454265422170?s=46

Jeg spurgte Elon Musks AI’s mening, er partnerskabet Roche & Herantis Pharma potentielt og levedygtigt. Svar: Først til at stoppe (eller helbrede) Parkinsons sygdom? Ikke helt – men banebrydende tiltag er på vej Parkinsons sygdom er brutal – ingen kur, kun symptombehandling. At “stoppe” progressionen er den hellige gral for sygdomsmodificerende behandlinger, og begge programmer fremhæver dette potentiale, men ingen af dem er der endnu: • HER-096: Frisk fra Fase 1b-succes (sikker, hjerne-penetrerende, stabile symptomer), plus en ren 6-måneders toksikologistudie i november 2025. Det er positioneret som en potentiel “først-i-klassen” til at standse progressionen ved at ramme grundårsagerne, med fulde biomarkører forventet i slutningen af 2025. Fase 2-effektivitetsresultater? Ikke før omkring 2027. Støttet af MJFF og Parkinson’s UK, er det lovende, men tidligt. • Roches Prasinezumab: Længere fremme i Fase III (starter sent 2025/tidligt 2026), med data der viser motorisk nedsættelse i undergrupper. Hvis det lykkes, kunne det være den første godkendte modificerende behandling til at bremse Parkinsons sygdom – ikke en kur, men et massivt fremskridt. Roche satser stort og kalder det en “revolution” inden for neurodegeneration. Ingen af dem er en kur (fuldstændig reversering af skader? Årtier væk, hvis nogensinde). Men prasinezumab kunne måske gøre krav på at være “først til at bremse” tidligere, mens HER-096 kunne differentiere sig på reparation. Hvis de indgik partnerskab, ville det være en kraftfuld kombination – synergistiske mekanismer, delte forsøg?

Herantis’ Antti Vuolanto var til Life Science Night for at fortælle om sin virksomhed.               Emner: 00:00 Herantis Pharma kort  01:56 Parkinsons sygdom: Stort udækket behov driver markedsvækst  07:29 HER-096  10:53 HER-096 Fase 1 Program  12:12 Partnerskab og finansieringsmål  13:48 Ekstern validering af HER-096 til sygdomsmodifikation ved Parkinsons  14:54 Spørgsmål og svar-session

I morgen deltager Herantis i Inderes’ virksomhedsaften, som inkluderer virksomhedens præsentation og en Q&A-session. Spørgsmål kan sendes via chat under arrangementet eller via forummet. Beskeder sendt her inden i morgen formiddag vil stadig nå frem.

Herantis Pharma              Herantis Pharma - How does HER-096 work in the body?    Innovative therapies for better lives

Bemærk, seneste tidsplaninfo!  Herantis forventer at rapportere biomarkørdata fra fase 1b inden midten af januar 2026, forud for JP Morgan Healthcare Conference-ugen i San Francisco, hvor selskabets ledelse vil være tilgængelig for møder.  Herantis planlægger at igangsætte et fase 2 klinisk forsøg i 2026 for at evaluere effektiviteten, sikkerheden og tolerabiliteten af HER-096 hos personer med Parkinsons sygdom.

Dette link indeholder nøgleinformationer om et godkendt, almindeligt anvendt lægemiddel til “behandling” af Parkinsons sygdom. Meget synes at være usikkert med hensyn til virkningsmekanismen og kontraindikationer. Forhåbentlig kommer Herantis Pharmas HER-096 på fast track            organon.com              sinemet_pi.pdf

Herantis Pharma

Herantis Pharma Plc – Company Release – December 11 2025, at 14.15 EET.Herantis Pharma Plc Financial Reporting and Annual General Meeting in 2026In 2026 Herantis Pharma Plc will publish its ...

Herantis Pharma Plc – Company Release – December 11 2025, at 14.15 EET.Herantis Pharma Plc Financial Reporting and Annual General Meeting in 2026In 2026 Herantis Pharma Plc will publish its financial reports as follows<table><tbody><tr><td>Report</td><td align="right">Release date</td></tr><tr><td>Financial Statements Release 2025</td><td align="right">5.3.2026</td></tr><tr><td>Annual Report for 2025</td><td align="right">30.3.2026</td></tr><tr><td>H1/2026 Half-a year report January-June</td><td align="right">20.8.2026</td></tr></tbody></table>Annual General Meeting 2026Herantis Pharma’s Annual General Meeting is scheduled for 23 April 2026. The Board of Directors will convene the meeting at a later date. The deadline for submission of proposals for the Annual General Meeting is 5 March 2026.The company's financial reviews are published in both Finnish and English through company releases and can be accessed on the company's website at <a href="https://herantis.com/investors/releases/">https://herantis.com/investors/releases/</a>.Herantis Pharma Plc observes a 30-day silent period prior to the publication of its financial statements and interim reports, during which the company does not comment on its financial position or outlook, nor meets with representatives of the capital markets or financial media.Herantis Pharma’s financial reporting calendar, silent periods, and the deadline for submitting proposals to the Annual General Meeting can also be found on our website at <a href="https://herantis.com/investors/calendar/">https://herantis.com/investors/calendar/</a>.Further informationTone Kvåle, CFOTel: +47 915 19576E-mail:&nbsp;<a href="mailto:ir@herantis.com">ir@herantis.com</a>Certified AdvisorUB Corporate Finance OyTel: +358 9 25 380 225E-mail:&nbsp;<a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease. The Company's lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson's disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson's patients.Herantis is listed on the Nasdaq First North Growth Market Finland. <a href="http://www.herantis.com">www.herantis.com</a>

Report	Release date
Financial Statements Release 2025	5.3.2026
Annual Report for 2025	30.3.2026
H1/2026 Half-a year report January-June	20.8.2026